FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and
bendamustine, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can
block cancer growth in different ways. Some block the ability of cancer cells to grow and
spread. Others find cancer cells and help kill them or carry cancer-killing substances to
them. It is not yet known whether giving fludarabine and cyclophosphamide together with
rituximab is more effective than giving bendamustine together with rituximab in treating
chronic lymphocytic leukemia.
PURPOSE: This randomized phase III trial is studying fludarabine, cyclophosphamide, and
rituximab to see how well they work compared with bendamustine and rituximab in treating
patients with previously untreated B-cell chronic lymphocytic leukemia.